Robert B Chao, MD doctorRBC
4 years 10 months ago
Self-monitoring app for AxSpA pts
⭐️adherence over 6 months poor 😔
⭐️high disease activity and older age related to ⬆️frequency of reporting
Abs#373
#ACR21
@RheumNow
Dr. John Cush RheumNow
4 years 10 months ago
This was in Lupus https://t.co/iqEPVFfHmc
Eric Dein ericdeinmd
4 years 10 months ago
Lupus Nephritis in pregnancy:
@HopkinsRheum Petri recommendations
⭐️AZA safe for LN, with tacro if needed
⭐️❌Voclosporin (alcohol content)
⭐️Belimumab uncertain
@Rheumnow #ACR21 Great Debate
CreakyJoints.org CreakyJoints
4 years 10 months ago
The good news: Most (around 90%) of people with chronic #inflammatory disease produced antibodies after the #COVID19 vaccine, but it was reduced compared to that of generally healthy people.
#ACR21 #Plenary
@alhkim https://t.co/KdWtIuuOtA
Danny Soulsby dsoulsMD
4 years 10 months ago
Dr. Eric Yen presenting about lupus nephritis mortality in the USA (1999-2019):
- Increasing trend in LN mortality x5 yrs
- Increased odds of death for Black pts > Latinx > API > AI/AN
- Urbanization (large central metro area) independent RF + effect modifier
#ACR21 https://t.co/qf61SkCqw4
Eric Dein ericdeinmd
4 years 10 months ago
#ACR21 Year in Review: TICOPSA - tight control treat to target in AxSpa does not meet primary endpoint, but favorable secondary outcomes. Was the control group at academic center already receiving good tight control? @Rheumnow
Patients with clinically suspect arthralgia can represent a challenge for clinicians, in a sense that there are not yet reliable markers to predict evolution to clinical RA nor enough evidence to support routine prescription of conventional synthetic DMARDS or biologic treatments in this setting.
Tanmayee Bichile, MD BichileT
4 years 10 months ago
The evolving JAK inhibitor story
Black box Warnings regarding JAK inhibitor use and MACE, malignancy, thrombosis and mortality - full safety data remains to be examined.
@ACRheum #ACRambassador #ACR21 https://t.co/imQ1LSxeXM
Eric Dein ericdeinmd
4 years 10 months ago
"We have to stop meeting like this" @DrDavidKarp @Rheumnow #ACR21. I was hoping to have some Ghirardelli chocolates in SF... But here's hoping for Philly cheesesteaks next year 🤞
Marie Kuchynski MD Doctorkuch
4 years 10 months ago
plenary I. #ACR21
Interesting data with the delta variant from @alhkim https://t.co/oUCOXSc9wA
EnvisionRheumat ERheumat
4 years 10 months ago
#ACR21 #ACR2021
Rheumatology Reproductive Health
👉🏻 Biologics and breast milk
👉🏻 Good vaccine response with TNFi (like with covid vaccines )
👉🏻 ustekimumab seems safe in pregnancy
👉🏻 Tofacitinib/ small molecules may cross placenta/ be in breast milk ➡️ contraindicated in preg/BF https://t.co/qk3sLR4QHz
Richard Conway RichardPAConway
4 years 10 months ago
@alhkim presenting COVaRiPAD data on SARS-CoV-2 vaccination. Most mount immune response. Risk of poor response BCDT >> MMF >> GCC > MTX/AZA/JAKi/TNFi > immunocompetent. Abstr#0457 #ACR21 @RheumNow https://t.co/lf8cAEWGXf
Robert B Chao, MD doctorRBC
4 years 10 months ago
Can we predict who which PsA pts will be radiographic progressors?
Abs#449 identified 103 candidate biomarker peptides corresponding to 69 proteins that could ID progressors
More data needed
#ACR21
@RheumNow
https://t.co/OLfPRNjTKV https://t.co/6UTn1J7nJH
Olga Petryna DrPetryna
4 years 10 months ago
Abst0437 #ACR21 @RheumNow factors assoctd w/poor response to mRNA Covid-19 vaccine in rheum pts Rx w/Rituxan: ⬆️ exposure to RTX over time, ⬇️ IgG levels prior to RTX, short interval btw RTX course & BNT162b2 vacc. RA highest&ANCA-vasculitis lowest probability for a + response. https://t.co/DsrJBlNvr7
